Gaithersburg, MD – According to filings with the U.S. Securities and Exchange Commission, Opgen is raising $10,000,000.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Timothy Dec played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Opgen

Located in Gaithersburg, MD, OpGen is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

To learn more about Opgen, visit http://www.opgen.com/

Contact:
Timothy Dec, Chief Financial Officer
301-869-9683
tdec@opgen.com
https://www.linkedin.com/in/tim-dec-274a2910/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved